BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18438865)

  • 1. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.
    Skhirtladze C; Distler O; Dees C; Akhmetshina A; Busch N; Venalis P; Zwerina J; Spriewald B; Pileckyte M; Schett G; Distler JH
    Arthritis Rheum; 2008 May; 58(5):1475-84. PubMed ID: 18438865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts.
    Akhmetshina A; Dees C; Pileckyte M; Szucs G; Spriewald BM; Zwerina J; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2008 Aug; 58(8):2553-64. PubMed ID: 18668558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
    Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis.
    Huber LC; Distler JH; Moritz F; Hemmatazad H; Hauser T; Michel BA; Gay RE; Matucci-Cerinic M; Gay S; Distler O; Jüngel A
    Arthritis Rheum; 2007 Aug; 56(8):2755-64. PubMed ID: 17665426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma.
    Pannu J; Gardner H; Shearstone JR; Smith E; Trojanowska M
    Arthritis Rheum; 2006 Sep; 54(9):3011-21. PubMed ID: 16947635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
    Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
    Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis.
    Maurer B; Stanczyk J; Jüngel A; Akhmetshina A; Trenkmann M; Brock M; Kowal-Bielecka O; Gay RE; Michel BA; Distler JH; Gay S; Distler O
    Arthritis Rheum; 2010 Jun; 62(6):1733-43. PubMed ID: 20201077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.
    Hemmatazad H; Rodrigues HM; Maurer B; Brentano F; Pileckyte M; Distler JH; Gay RE; Michel BA; Gay S; Huber LC; Distler O; Jüngel A
    Arthritis Rheum; 2009 May; 60(5):1519-29. PubMed ID: 19404935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis.
    Distler JH; Jüngel A; Pileckyte M; Zwerina J; Michel BA; Gay RE; Kowal-Bielecka O; Matucci-Cerinic M; Schett G; Marti HH; Gay S; Distler O
    Arthritis Rheum; 2007 Dec; 56(12):4203-15. PubMed ID: 18050252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
    Ong VH; Evans LA; Shiwen X; Fisher IB; Rajkumar V; Abraham DJ; Black CM; Denton CP
    Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis.
    Yasuoka H; Jukic DM; Zhou Z; Choi AM; Feghali-Bostwick CA
    Arthritis Rheum; 2006 Sep; 54(9):3001-10. PubMed ID: 16947625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.
    Pannu J; Gore-Hyer E; Yamanaka M; Smith EA; Rubinchik S; Dong JY; Jablonska S; Blaszczyk M; Trojanowska M
    Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.
    Distler JH; Jüngel A; Caretto D; Schulze-Horsel U; Kowal-Bielecka O; Gay RE; Michel BA; Müller-Ladner U; Kalden JR; Gay S; Distler O
    Arthritis Rheum; 2006 Jan; 54(1):214-25. PubMed ID: 16385517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.
    Chen Y; Leask A; Abraham DJ; Pala D; Shiwen X; Khan K; Liu S; Carter DE; Wilcox-Adelman S; Goetinck P; Denton CP; Black CM; Pitsillides AA; Sarraf CE; Eastwood M
    Arthritis Rheum; 2008 Feb; 58(2):577-85. PubMed ID: 18240216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
    Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD40-CD154 interaction in tissue fibrosis.
    Kawai M; Masuda A; Kuwana M
    Arthritis Rheum; 2008 Nov; 58(11):3562-73. PubMed ID: 18975310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.